Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
San Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.”
AstraZeneca announced that the company’s Brilinta (ticagrelor) hit the primary endpoint in the Phase III THALES trial in stroke.
The U.S. FDA granted Orphan Drug Designation for OBI Pharma Inc.’s first-in-class antibody drug conjugate (ADC) OBI-999 for the treatment of pancreatic cancer.
The U.S. FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.
Seattle Genetics is looking for a quicker path to resolution with Daiichi Sankyo over antibody drug conjugate technology that both companies claim ownership of.
Tokyo-based Daiichi Sankyo’s ESAX-DN Phase III trial of esaxerenone met the primary endpoint in diabetic nephropathy.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates (ADCs) during a partnership that spanned seven years.
Seattle Genetics Inc. responded to Daiichi Sankyo Co. Ltd.’s filing of a Declaratory Judgment action alleging the biotechnology company is not entitled to intellectual property rights under a collaboration between them for the development of antibody-drug conjugates (ADCs).
The U.S. Food and Drug Administration granted earlier-than-expected approval to Roche Holding AG’s antibody-drug conjugate Polivy for the treatment of patients with advanced lymphoma.
